- Home
- MITQ vs BIAF Comparison
MITQ vs BIAF Comparison
Compare MITQ & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MITQ | BIAF |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 6.6M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MITQ | BIAF |
|---|---|---|
| Price | $0.72 | $1.65 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 72.1K | ★ 99.0K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,477,000.00 | $6,776,739.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.50 | $1.25 |
| 52 Week High | $1.66 | $46.53 |
Technical Indicators
Market Signals| Indicator | MITQ | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 44.72 |
| Support Level | $0.70 | $1.34 |
| Resistance Level | $0.80 | $1.79 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 63.29 | 74.09 |
Price Performance
Historical ComparisonAbout MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.